Article Text

Download PDFPDF

SAT0005 DETECTION OF HIGHLY EXPANDED T CELL CLONES IN THE PERIPHERAL BLOOD OF AT RISK INDIVIDUALS FOR RHEUMATOID ARTHRITIS BEFORE THE CLINICAL ONSET OF THE DISEASE
  1. Céline Lamacchia1,
  2. Zuleika Calderin1,
  3. Delphine Courvoisier1,
  4. Denis Mongin1,
  5. Stéphane Buhler1,
  6. Gaby Palmer2,
  7. Olivia Studer1,
  8. Cem Gabay1,
  9. Jean Villard1,
  10. Axel Finckh1
  1. 1University Hospitals of Geneva, Geneva, Switzerland
  2. 2University of Geneva School of Medicine, Geneva, Switzerland

Abstract

Background: Rheumatoid arthritis (RA) is an autoimmune disease with unknown etiopathogenesis. Systemic autoimmunity precedes clinical disease onset, and current evidence suggests that the immune onset of RA takes place outside of the joints several years before clinical manifestations. Expanded T cell clones can be found in the synovial tissue of established RA patients. The mechanisms by which systemic immune abnormalities progress to joint-specific autoimmunity are not yet understood.

Objectives: To examine if expanded T cell clone signatures can be detected in the peripheral blood before the development of clinical RA.

Methods: Next-generation sequencing of the T Cell Receptor β (TCRβ) CDR3 repertoire was performed on genomic DNA isolated from blood samples of individuals genetically at risk for RA, namely first-degree relatives of RA patients (RA-FDR) at different pre-clinical phases of disease development (SCREEN-RA cohort), and of matched RA patients used as a control group (SCQM cohort). All individuals were matched for age and sex, and categorized into four groups (n=20/group): Group 1: “healthy” asymptomatic RA-FDR without autoantibodies or symptoms associated with possible RA. Group 2: Asymptomatic RA-FDR with evidence of ‘systemic autoimmunity associated with RA’ defined by high levels of anti-citrullinated peptide antibodies (ACPA; 3x≥ ULN). Group 3: RA-FDR having presented undifferentiated arthritis (n=8) or having developed classifiable RA after inclusion (n=12). Group 4: patients with established RA of less than 3 years duration. T cell clones were identified by their unique TCRβ CDR3 sequence. Clones with a frequency over 0.5% were considered to be highly expanded clones (HEC). Both absolute number and frequency of productive T cell clones was compared between the 4 groups using mixed effect regression models to account for matching.

Results: As expected, the large majority of clones in the peripheral blood were detected at very low frequency (<0.1%) in all groups (Figure 1A). Interestingly, expanded clones (>0.1% of total TCR analysed) tended to occur more frequently in later preclinical phases and established disease. A significant difference among groups was observed for highly expanded clones (HEC) (p=0.001). Specifically, the absolute number of HEC was significantly higher in RA patients (group 4; mean 4.65, p=0.003) and tended to be higher in symptomatic RA-FDR (group 3; mean 3.4, p=0.07) compared to “healthy” RA-FDR (group 1; mean 1.55) (Figure 1B). A trend towards a higher frequency of the top 50 expanded clones was also observed in symptomatic RA-FDR (group 3; mean 0.17%) compared to “healthy” RA-FDR (group 1; mean 0.11%). At risk individuals defined by the presence of high ACPA levels (group 2) did not differ from “healthy” RA-FDR in terms of absolute number and frequency of clones.

Conclusion: For the first time, highly expanded T cell clones were detected in the peripheral blood of at risk individuals before the clinical onset of RA, in particular in the later pre-clinical phases of RA development. Tracking these dominant T cell clones in longitudinal analyses and elucidating their role might help to better understand the earliest pathogenic events in RA.

Reference [1] Catrina AI et al. Nat Rev Rheumatol. 2017;13(2):79-86; Klarenbeek PL et al. Ann Rheum Dis. 2012;71(6):1088-93

Figure 1

Absolute number of productive TCR clones by clonal size. (A) Bars show mean and standard error of the mean (mixed effect regression model). (B) Each dot represents the HEC number observed for 1 individual (mixed effect regression model).

Disclosure of Interests: Céline Lamacchia: None declared, Zuleika Calderin: None declared, Delphine Courvoisier Grant/research support from: has received an unrestricted grant from MSD for this study, Consultant for: has received consulting fees from BMS, Pfizer, AB2 Bio and Janssen., Paid instructor for: Janssen, Denis Mongin: None declared, Stéphane Buhler: None declared, Gaby Palmer: None declared, Olivia Studer: None declared, Cem Gabay Grant/research support from: Roche, Pfizer, AB2 Bio Ltd, Consultant for: Roche, Pfizer, Lilly, AbbVie, Sanofi, Regeneron, Bristol-Myers Squibb, Novartis, UCB, AB2 Bio Ltd, Debiopharm, Jean Villard: None declared, Axel Finckh Grant/research support from: Bristol-Myers Squibb, Pfizer Inc, Consultant for: AbbVie, A2Bio, Bristol-Myers Squibb, MSD, Roche, Pfizer Inc, and UCB

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.